Introduction to Pharmacogenomics Flashcards
Which of the following is/are true regarding the potential benefits of pharmacogenomics?
A. More powerful medicines and lesser side effects B. Better vaccines C. Decreased cost of hospitalization D. All of the above E. Only A and B are correct
D
Genetic polymorphism may arise because of the following:
A. Pharmacodynamic variation as in the case of G6PD resulting in xenobiotic induced hemolysis.
B. Polymorphism in the mitochondrial DNa as in the case of aminoglycoside induced deafness.
C. Pharmacokinetic variation requiring increased dosage of warfarin due to warfarin resistance.
D. A and B only
E. All of the above
D
Variability in drug response may be due to the following intrinsic factors except:
a. genetic differences
b. developmental stage
c. drug interaction
d. sex
e. none of the above
C
The following may be examples of gene and environment interaction
a. hemolysis from naphthalene exposure secondary to G6PD deficiency
b. cyanosis in young infant with methemoglobin reductase deficiency following exposure to well water containing nitrates
c. toxicity from lead even if the blood level is low
d. all of the above
e. only a and b are correct
B
Protection or susceptibility to cancer when exposed to certain xenobiotics may be associated with genes that code for
a. GSTM
b. NAT2
c. CYP2D6
d. only a and b are correct
e. all of the above
B
The following statements is/are true
a. when quinidine is taken as prophylaxis from malaria, CYP2D6 will be inhibited, therefore the dose of metoprolol should be increased to control hypertension effectively
b. in the presence of thiopurine S methyltransferase deficiency, the dose of 6 mercaptopurine may be
decreased to as low as 5% of the standard dose
c. NAT 1 polymorphism is associated more with the slow acetylator phenotype and urinary bladder cancer
d. all of the above
e. only a and b are correct
E
Which of the following phase 2 metabolizing enzymes require a very significant dose reduction in the presence of a deficiency
a. CYP2D6
b. CYP2C9
c. TPMT
d. NAT2
e. only a and b are correct
C
The following condition/s is/are associated with polymorphisms resulting from pharmacodynamic variations
a. slow acetylator phenotype
b. aminoglycoside induced deafness
c. warfarin resistance
d. warfarin sensitivity
C
Pharmacokinetic variations may involve any of the following
a. transporters
b. metabolizing enzymes
c. receptors
d. only a and b are correct
e. all of the above
D
Hemolysis associate with the anti-malarial primaquine
A. N-acetyl transferase
B. G6PD deficiency
C. pseudocholinesterase deficiency
D. methemoglobin reductase deficiency
B
Prolonged apnea from the use of succinylcholine
A. N-acetyl transferase
B. G6PD deficiency
C. pseudocholinesterase deficiency
D. methemoglobin reductase deficiency
C
Trimodal distribution (fast, intermediate, slow) of isoniazid metabolism
A. N-acetyl transferase
B. G6PD deficiency
C. pseudocholinesterase deficiency
D. methemoglobin reductase deficiency
A
Cyanosis associated with abnormal hemoglobin following exposure to xenobiotics
A. N-acetyl transferase
B. G6PD deficiency
C. pseudocholinesterase deficiency
D. methemoglobin reductase deficiency
D
In patients given isoniazid, analysis of parent compound and metabolites in urine differentiates fast from slow acetylators
A. ecogenetics research B. genetic polymorphism C. phenocopy D. phenotype test E. genotyping study
D
Intake of drugs that inhibit the CYP2D6 such as quiniline
A. ecogenetics research B. genetic polymorphism C. phenocopy D. phenotype test E. genotyping study
C
